Cantor Keeps Merck (MRK) at Neutral Amid Gardasil Dosage Review By ACIP.

Merck & Co., Inc. (NYSE:MRK) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Cantor Fitzgerald reaffirmed its Neutral rating on Merck & Co., Inc. (NYSE:MRK) with a fixed price target of $85 per share. Carter Gould, the firm’s analyst, offered insight concerning Merck’s Gardasil vaccine, which has raised investor concerns because of possible modifications to suggested dosage schedules.

It was originally anticipated that the Advisory Committee on Immunization Practices (ACIP) would suggest a schedule of 1-2 doses of Gardasil; this recommendation could have an effect on the vaccine’s projected sales in the United States. Although there was evident motion in this approach, Gould pointed out that the anticipated risk to Merck’s 2025 sales may be exaggerated. He added that known clinician behaviors, usage trends, and Merck’s potential pricing plans could all help to offset any possible drops in sales.

Gould also emphasized the new ambiguities surrounding the ACIP’s position, implying that these could make it more likely that the committee will approve a 1-2 dose regimen at the next June meeting.

Merck & Co., Inc. (NYSE:MRK) is a well-known American multinational pharmaceutical firm. Internationally recognized as Merck Sharp & Dohme (MSD), the company is a global provider of prescription medications, vaccines, biologic therapies, and animal health products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.